With more the 50% of CTI's active prospective studies involving regenerative medicine, including contributing to the development program of several of the world's first approved gene therapy products, the company is a leader in the field.

CTI has the expertise needed to help our sponsors understand and comply with document submission requirements.

There's a reason we have one of the highest retention rates in the industry. We value our people, and we work hard to make sure our team members know it.